Introduction
According to the World Health Organization, medication non-compliance or nonadherence has emerged as a major problem in developing countries where only 50% adherence has been found among patients with a long-term illness and the problem is expected to be greater in underdeveloped countries in view of the prevailing dearth of health care resources and disparities in health care delivery [1] . A meta-analysis of 376,162 patients established the positive effect of guideline-directed medical therapy (GDMT) for both the primary and secondary prevention of cardiovascular disease (CVD) and concluded that measures to improve overall adherence are desirable as opposed to class-specific adherence [2] . A meta-analysis of 21 studies revealed that GDMT can reduce the risk of all-cause mortality by 40% and cardiovascular events by 30% in patients with established CVD [3] . Similarly, a dose-response analysis discovered that higher compliance with antihypertensive medication was associated with a lower risk of both hemorrhagic and ischemic stroke [4] . Therefore, nonadherence to antihypertensive medications has shown to increase both cardiovascular and cerebrovascular events (CCE) and related mortality [5] . Multiple factors can contribute towards poor adherence which can be divided into socioeconomic, motivational, and communicational causes [6] . Earlier studies have evaluated the outcomes in the form of mortality and cost of care related to non-compliance to a group of medications mainly including antihypertensive, antidiabetics, or lipid-lowering agents [7] [8] [9] . However, studies describing the sequential intersection of multiple sociodemographic and comorbid variables influencing medication non-compliance and cardiovascular outcomes would be crucial to perform as prior studies have called for improvement in overall patient adherence/compliance rather than just towards a class of medication [2] . Hence, using a nationally representative cohort from the National Inpatient Sample (NIS) databases (2007-2014), we postulate to reveal the rising prevalence and concerning trends in medication non-compliance, all-cause inpatient mortality, and CCE among patients with non-compliant behaviors irrespective of class of medications. We also compared characteristics and manifest comorbidities in non-compliant patients with and without incidental CCE.
Materials And Methods

Data source
This retrospective study analyzed the NIS databases (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , which is a division of the Healthcare Cost and Utilization Project, developed by the Agency for Healthcare Research and Quality. The NIS is the largest publicly available hospital discharge administrative database consisting of 20% stratified sampling of all inpatient admissions (more than seven million hospital stays per year) to non-federal hospitals in the United States. Considering the deidentified nature of the admission records, an approval from the institutional review board was not mandatory for this study.
Study population and variables
From January 2007 to December 2014, adult patients were identified with a non-compliant behavior towards medications using the International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic code V15.81 [10] . These patients were divided into two study groups: those who experienced CCE vs. those who did not. We evaluated the frequency of various CCE which included first or subsequent myocardial infarction (MI), first or subsequent stroke, out of hospital cardiac arrest, arrhythmias, and venous thromboembolism (Appendix). The details of NIS data on variables, demographics, hospital-level characteristics, and comorbidities have been published previously [11] [12] [13] . We examined and compared the following baseline variables between the two groups: demographics, the source of payer and median household income quartile for patients' zip code, hospital-related variables, and preexisting comorbidities.
Primary and secondary outcomes
The primary outcomes were defined as in-hospital mortality, disposition, and health care resource utilization in terms of mean length of stay (LOS, days) and hospital charges (USD). The secondary outcomes were the trends in all-cause in-hospital mortality and CCE in patients admitted with medication nonadherence regardless of medication group from 2007 to 2014.
Statistical analyses
Statistical analyses were performed using SPSS V.22.0 (IBM Corp., Armonk, NY, USA). Pearson's chi-square test is used for the categorical variables which were presented as numbers and proportions, and the Student t-test was used for the continuous variables which were presented as the mean and standard deviation. Furthermore, we stratified the population into the age groups of 18-44, 45-64, and ≥65 years. A two-sided p-value ≤0.05 was defined as a statistical significance.
Results
From 2007 to 2014, we identified a total of 7,453,831 hospitalizations among the adult population with a history of medication nonadherence. Of these, 867,997 (11.6%) patients experienced in-hospital CCE. Table 1 displays the patients and hospital-related characteristics as well as pre-existing comorbidities in nonadherent adults with and without CCE. Patients non-compliant to medications who experienced CCE consisted of higher number of older (mean age 59.6 vs. 51.0 years, 45-64 years: 50.1% vs. 43.8%), white (58.0% vs. 50.5%), male (62.1% vs. 37.9%) patients. The CCE cohort more often consisted of Medicare enrollees (44.5% vs. 39.6%) and had emergency admissions (95.1% vs. 91.9%). The Southern and West regions documented a higher number of CCE among non-compliant patients. The incidence of major comorbid risk factors such as diabetes, hypertension, obesity and dyslipidemia, peripheral vascular disease, smoking, chronic pulmonary disease, coagulopathy, renal failure, as well as valvular heart disease was also higher in patients with CCE. Figure 2 demonstrates in-hospital outcomes as well as mean LOS and hospital charges with or without CCE in patients with medication non-compliance. All-cause in-hospital mortality was significantly higher in patients with CCE compared to without such events (3% vs. 0.7%). In terms of disposition, the non-CCE group had a significantly lower number of routine discharges than patients with CCE (59.4% vs. 71.1%), whereas a greater number of transfers were associated with the CCE group (4.4% vs. 1.8% transfers to short-term hospitals and 17.6% vs. 11.6% other transfers including skilled nursing facility, intermediate care facility, etc.). Though the mean LOS was equivalent in both the groups, mean hospital charges were considerably higher in non-compliant patients with CCE vs. without CCE ($52,740 vs. $30,748). 
Discussion
Our findings obtained in a study of a large nationwide cohort indicated that nearly 12% of patients hospitalized with a history of medication non-compliance developed CCE and had suffered higher in-hospital mortality, upward trends in all-cause mortality and in-hospital cardiovascular complications, and higher resource utilization as compared to non-compliant patients without CCE. Patients developing CCE had a lower rate of routine discharge and a higher rate of transfers to other facilities and requirement of home health care. The health care cost was also significantly higher in non-compliant patients with CCE. Our study showed increasing trends in the in-hospital mortality and complications related to CCE from 2007 to 2014.
Adherence is a challenge mainly for chronic diseases, especially during the symptom-free intervals. The consequences of nonadherence are disease mismanagement, progression, and development of complications which lead to increased use of medical resources in the form of frequent health care visits, dependence on health care facilities and hospitalizations, and all these lead to poor outcomes in terms of quality of life, increased mortality, and greater cost of care [14] . In the United States, excess hospitalizations due to medication nonadherence cost approximately $100 billion every year [15] . Several studies have found that overall health care costs are much higher for patients with poor adherence as compared to patients with good adherence. A review summarizing the impact of nonadherence on health care cost in several chronic diseases such as diabetes, CVD, and chronic obstructive pulmonary disease concluded that increasing the medication adherence significantly reduces the overall health care cost [16] . Our prior analyses have revealed close etiopathological and prognostic link of cardiovascular disorders and outcomes with endocrine, respiratory, or psychiatric disorders which also suggests that medications targeted for one organ system can help prevent overall complications, improve quality of life, and improve long-term prognosis [13, [17] [18] [19] [20] [21] .
Correspondingly, several studies have described how nonadherence increases individual comorbid diseases or risk factors and in turn, in-hospital mortality. One study by Rasmussen et al. explored the association between drug adherence and mortality in survivors of acute MI which showed that in comparison with the patients with high levels of adherence to statins, the risk of mortality was 25% higher among patients with poor adherence [22] . Similarly, one study assessing the risk of fatal stroke associated with nonadherence to statin and antihypertensive therapy derived that individuals with hypercholesterolemia and hypertension who failed to take their prescribed medications experienced a substantially increased (up to twice) risk of fatal stroke [23] . Studies have established the demographics of patients more frequently found to be linked to medication non-compliance. As one leap forward, we studied the baseline characteristics and comorbidities among non-compliant patients with CCE and compared it to patients without CCE to help clinicians to understand the demographics of the nonadherent high-risk patient population. We observed that the patients with CCE were older, more frequently white, men and had a higher prevalence of comorbidities. Non-compliant patients developing CCE had worse outcomes, underwent excessive health care utilization (transfers to short-term hospitals, intermediate care, and skilled nursing facilities, home health care) and in turn, the higher cost of care per admission. Our findings from a much larger patient population linking the medication nonadherence to in-hospital outcomes expand the literature on nonadherence and emphasize the importance of medication adherence in clinical practice.
The challenge with medication nonadherence is that there does not exist a particular parameter to measure it and it is invisible to patients, families, and health care providers. To deal with the emerging concerns pertinent to nonadherence, we should identify the barriers related to nonadherence which come under the categories of patient-related factors which include poor knowledge (most common predictor), lack of motivation, depression, denial, and cultural beliefs; treatment-related factors which include the type of illness, complexity of treatment, side effects, cost, and others most importantly physician-patient relationship [24, 25] . Then comes the methods of measuring nonadherence such as directly observed therapy, identifying the level of medicine in the blood (most reliable); indirect methods such as patient questionnaires, pill counts, clinical response, electronic monitors, patient diary, and many more [26] . Even after incorporating different interventions to increase the drug adherence including prescribing generic medications, simplifying the schedule, patients' health coaching, close follow-up, frequent communication with treating physicians, and using mobile health care applications [26] [27] [28] [29] , there are number of population-based studies showing the decreasing compliance rate for multiple medications in the short term and long term [30] . The trends in hospitalizations with worsened outcomes heightened complications, and health care costs related to medication nonadherence were consistently evident from our study results.
Limitations
This study has several limitations. The current analysis does not reveal nonadherence to a specific group of medication or disease. Because of the retrospective nature of the study, it represents only an association and not causation. Over-or underreporting of the study population could be likely secondary to administrative coding errors in the NIS database. Despite a few limitations, a large sample size increases the generalizability of the study findings.
Conclusions
In this population-based nationwide analysis, we observed concerning trends in the prevalence of medication non-compliance and related CCE among hospitalized adults from 2007 to 2014 which was associated with higher in-hospital mortality, health care utilization, and cost. This study highlights the role of health care practitioners in screening older patients with chronic conditions for poor medication compliance and incorporating a more robust and collaborative approach which may possibly make a difference in clinical medicine on a global level. 
Appendices
Cardiovascular Events and Outcomes
CCS is based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), and a uniform and standardized coding system. The ICD-9-CM's multitude of codes -over 14,000 diagnosis codes and 3,900 procedure codes -are collapsed into a smaller number of clinically meaningful categories that are sometimes more useful for presenting descriptive statistics than are individual ICD-9-CM codes. 
